A retrospective analysis of the AVAglio study showed OS benefits for patients with isocitrate dehydrogenase 1 (IDH1) WT proneural GBM when bevacizumab was combined with the standard regimen [23]. This evidence concerns the gene IDH1 and glioblastoma.